Portage Biotech Announces Participation in January 2022 Investor Conferences
As part of the Company’s participation, CEO Dr.
Registration and other details for each event are as follows:
11th Annual LifeSci Partners Corporate Access Event
Format: 1-on-1 investor meetings
Registration - https://lifesci.events/LifeSci2022
H.C. Wainwright BioConnect Conference
Format: 1-on-1 investor meetings; on demand pre-recorded presentation available through conference portal
New Directions in Immuno-Oncology
B. Riley Securities’
Format: Fireside chat
Portage is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of the most promising clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage’s portfolio consists of five diverse platforms, leveraging delivery by intratumorals, nanoparticles, liposomes, aptamers, and virus-like particles. Within these five platforms, Portage has 10 products currently in development with multiple clinical readouts expected over the next 12-24 months. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at
This news release contains statements about the Company’s information that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.
FOR MORE INFORMATION, PLEASE CONTACT:
Source: Portage Biotech, Inc.